Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats

Neuroscience Research

Volumn 60, Issue 4, 2008, Pages 355-363

  Shimizu, Masako ^a   Miyazaki, Ikuko ^a   Higashi, Youichirou ^a   Eslava Alva, Maria J ^a   Diaz Corrales, Francisco J ^a   Asanuma, Masato ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

L DOPA; Motor neuron; PAG608; Parkinson's disease

Indexed keywords

CARBIDOPA; LEVODOPA; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; GENE; GENE EXPRESSION; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; MOTONEURON; NONHUMAN; PAG608 GENE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD VENTRAL HORN; THALAMUS NUCLEUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; LEVODOPA; MOTOR NEURONS; NUCLEAR PROTEINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 40649126100     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.12.006     Document Type: Article

References (36)

1. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16 (2001) 448-458
2. Asanuma M., Miyazaki I., Diaz-Corrales F.J., and Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med. Okayama 58 (2004) 221-233
3. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Shimizu M., Tanaka K., and Ogawa N. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro. Neurol. Res. 27 (2005) 533-539
4. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
5. Bar-Peled O., Knudson M., Korsmeyer S.J., and Rothstein J.D. Motor neuron degeneration is attenuated in bax-deficient neurons in vitro. J. Neurosci. Res. 55 (1999) 542-556
6. Basma A.N., Morris E.J., Nicklas W.J., and Geller H.M. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem. 64 (1995) 825-832
7. Batulan Z., Taylor D.M., Aarons R.J., Minotti S., Doroudchi M.M., Nalbantoglu J., and Durham H.D. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol. Dis. 24 (2006) 213-225
8. Berman S.B., Zigmond M.J., and Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67 (1996) 593-600
9. Carriedo S.G., Yin H.Z., and Weiss J.H. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16 (1996) 4069-4079
10. Datla K.P., Blunt S.B., and Dexter D.T. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 16 (2001) 424-434
11. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., and Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
12. Ferrario J.E., Delfino M.A., Stefano A.V., Zbarsky V., Douhou A., Murer M.G., Raisman-Vozari R., and Gershanik O.S. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci. Res. 47 (2003) 431-436
13. Galcheva-Gargova Z., Gangwani L., Konstantinov K.N., Mikrut M., Theroux S.J., Enoch T., and Davis R.J. The cytoplasmic zinc finger protein ZPR1 accumulates in the nucleolus of proliferating cells. Mol. Biol. Cell 9 (1998) 2963-2971
14. Gillardon F., Spranger M., Tiesler C., and Hossmann K.A. Expression of cell death-associated phospho-c-Jun and p53-activated gene 608 in hippocampal CA1 neurons following global ischemia. Mol. Brain Res. 73 (1999) 138-143
15. Hermann D.M., Kuroiwa T., Hata R., Gillardon F., Ito U., and Mies G. Expression of redox factor-1, p53-activated gene 608 and caspase-3 messenger RNAs following repeated unilateral common carotid artery occlusion in gerbils-relationship to delayed cell injury and secondary failure of energy state. Neuroscience 102 (2001) 779-787
16. Higashi Y., Asanuma M., Miyazaki I., Haque M.E., Fujita N., Tanaka K., and Ogawa N. The p53-activated gene, PAG608, requires a zinc finger domain for nuclear localization and oxidative stress-induced apoptosis. J. Biol. Chem. 277 (2002) 42224-42232
17. Israeli D., Tessler E., Haupt Y., Elkeles A., Wilder S., Amson R., Telerman A., and Oren M. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J. 16 (1997) 4384-4392
18. Kostrzewa R.M., Kostrzewa J.P., and Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 23 (2002) 57-63
19. Lai C.T., and Yu P.H. Dopamine- and L-b-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53 (1997) 363-372
20. Lambrechts D., Robberecht W., and Carmeliet P. Heterogeneity in motoneuron disease. Trends Neurosci. 30 (2007) 536-544
21. Mendez-Vidal C., Prahl M., and Wiman K.G. The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs. FEBS Lett. 580 (2006) 4401-4408
22. Mendez-Vidal C., Wilhelm M.T., Hellborg F., Qian W., and Wiman K.G. The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. Nucleic Acids Res. 30 (2002) 1991-1996
23. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., and Ogawa N. Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro. Clin. Neuropharmacol. 28 (2005) 155-160
24. Mytilineou C., Han S.K., and Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem. 61 (1993) 1470-1478
25. Mytilineou C., Walker R.H., JnoBaptiste R., and Olanow C.W. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304 (2003) 792-800
26. Offen D., Ziv I., Sternin H., Melamed E., and Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141 (1996) 32-39
27. Ogawa N., Edamatsu R., Mizukawa K., Asanuma M., Kohno M., and Mori A. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv. Neurol. 60 (1993) 242-250
28. Ogawa N., Tanaka K., and Asanuma M. Bromocriptine markedly suppress levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem. Res. 25 (2000) 755-758
29. Olanow C.W., and Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov. Disord. 20 Suppl. 11 (2005) S3-S10
30. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., and De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682 (1995) 133-143
31. Pellegrino L.J., Pellegrino A.S., and Cushman A.J. A Stereotaxic Atlas of the Rat Brain (1979), New York and London, Plenum Press
32. Tomasevic G., Shamloo M., Israeli D., and Wieloch T. Activation of p53 and its target genes p21(WAF1/Cip1) and PAG608/Wig-1 in ischemic preconditioning. Mol. Brain Res. 70 (1999) 304-313
33. Varmeh-Ziaie S., Okan I., Wang Y., Magnusson K.P., Warthoe P., Strauss M., and Wiman K.G. Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene 15 (1997) 2699-2704
34. Walkinshaw G., and Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95 (1995) 2458-2464
35. Waza M., Adachi H., Katsuno M., Minamiyama M., Tanaka F., Doyu M., and Sobue G. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med. 84 (2006) 635-646
36. Yang M., May W.S., and Ito T. JAZ requires the double-stranded RNA-binding zinc finger motifs for nuclear localization. J. Biol. Chem. 274 (1999) 27399-27406